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Methods and analyses:
One hundred women with previous GDM will be randomised to either liraglutide or placebo treatment for 1 year (blinded) with an open-label extension for another 4 years. Additionally, 15 women without previous GDM will constitute a baseline control group. Women will be tested with an oral glucose tolerance test (primary endpoint: area under curve for plasma glucose) and an isoglycaemic intravenous glucose infusion at baseline, after one year, and after five years. Additional evaluations include a glucagon test, dual-energy X-ray absorptiometry, imaging of the liver (ultrasound elastography and fibro-scanning), an ad libitum meal for food intake evaluation and questionnaires related to appetite, quality of life and alcohol consumption habits.
Ethics and dissemination:
The protocol has been approved by the Danish Medicines Agency, the Scientific-Ethical Committee of the Capital Region of Denmark, and the Danish Data Protection Agency and will be carried out under the surveillance and guidance of the GCP unit at Copenhagen University Hospital Bispebjerg in compliance with the ICH-GCP guidelines and in accordance with the Helsinki Declaration. Positive, negative, and inconclusive results will be published at scientific conferences and as one or more scientific manuscripts in peer-reviewed journals.
Registrations:
The trial is registered at https://eudract.ema.europa.eu (2012-001371-37) and www.clinicaltrials.gov (NCT01795248). 
ARTICLE SUMMARY

Article focus
• This article describes a study protocol for a randomised, placebo-controlled trial evaluating the effect of the glucagon-like peptide-1 receptor agonist, liraglutide, in patients with previous gestational diabetes mellitus
• We hypothesise that the glucose tolerance after an oral glucose challenge, one and five years after study commencement, is superior after liraglutide compared to placebo treatment
Key messages
• Women with previous gestational diabetes mellitus are at high risk of developing type 2 diabetes later in life • This will be the first study investigating the effect of a glucagon-like peptide-1 receptor agonist on the risk of developing type 2 diabetes in women with previous gestational diabetes mellitus
• Women with previous gestational diabetes mellitus constitute a high-risk group and, thus, a unique opportunity to investigate the early development of type 2 diabetes
Strengths and limitations of this study
• Participants will be monitored extensively during a 1-year blinded phase and throughout a 4-year extension period
• Although all eligible women from a large part of Denmark has been invited to the study, the study population may not be fully representative
• The study may not be powered to conclude on the secondary endpoints 
INTRODUCTION
Women with previous gestational diabetes mellitus represent a high-risk group
Pregnancy is associated with insulin resistance (1). This is normally compensated for by increased pancreatic insulin secretion, resulting in retained normal glucose tolerance (NGT) (2) . Women with gestational diabetes mellitus (GDM) are not capable of increasing their insulin secretion enough to compensate for pregnancyinduced insulin resistance, resulting in abnormal glucose tolerance. In the majority of women, glucose tolerance is re-established after delivery. Nevertheless, most women with previous GDM are at high risk of developing T2D later in life (3,4).
Bellamy et al.
state that up to 63% of women with GDM develop T2D within 16 years (5), Bian et al. describe a risk of 33% for the development of T2D from 5-10 years after GDM (6) , and a Danish study reports a risk of 40% for the development of T2D 7 years after diet-treated GDM (3). Insulin dependency, high plasma glucose (PG) levels during oral glucose tolerance test (OGTT), difficult controllable glycaemia (need of insulin-treatment), and high body mass index (BMI) during pregnancy are strong predictors of the risk of T2D after GDM (4).
The early pathophysiology of type 2 diabetes remains elusive
Studies show that, on average, patients with T2D are diagnosed when their relative beta cell function is approximately 50% of normal (7) . The delayed onset of symptoms makes it difficult to characterise the pathogenesis of T2D. There is general agreement that both insulin resistance and abnormal insulin secretion co-exist in T2D. Nevertheless, the order in which the pathophysiological characteristics of T2D occur remains unclear (8) . Studies of first-degree relatives of patients with T2D have yielded conflicting results regarding whether abnormal insulin secretion or insulin resistance is the primary defect in the disease (9) (10) (11) (12) (13) (14) (15) (16) (17) . Other physiological defects have been suggested as primary pathogenic defects. These include decreased firstphase insulin response and impaired incretin effect (decreased beta cell response to the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)). In healthy subjects, both incretin hormones possess strong glucose-dependent insulinotropic properties and enhance glucose- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   5 induced insulin secretion from the beginning of a meal (18) (19) (20) . This potentiation of insulin secretion after oral glucose ingestion is called the incretin effect, and is illustrated when orally administered glucose elicits a greater insulin response than intravenous glucose at identical PG profiles. Patients with T2D exhibit impaired incretin effect. The cause of this pathophysiological trait is unclear (21) (22) (23) .
Understanding the pathophysiology in the early stages of T2D may provide new and effective interventions aiming at preventing the development of the disease. One approach to achieve this is to prospectively follow a high-risk group. 
OBJECTIVE
Because of their high risk of developing T2D, overweight and obese non-diabetic women with previous GDM provide an opportunity for investigating how the early stages of T2D develop and whether GLP-1R agonists prevent or delay the onset of T2D. The primary objective of the present protocol is to assess whether treatment with the GLP-1R agonist liraglutide reduces the risk of T2D in women with previous GDM. Simultaneously, the developmental trajectories of pathophysiological defects known from patients with T2D will be evaluated. Such information will ultimately contribute to a clarification of the pathogenesis of T2D and provide a basis for preventive measures and interventions. We hypothesise that women with previous GDM receiving liraglutide treatment for a year will have a smaller area under the curve (AUC) for PG during an OGTT carried out after one week of wash-out (primary endpoint) than women with previous GDM treated with placebo. The primary endpoint will be re-evaluated after another 4 years of liraglutide treatment or no intervention. Secondary endpoints include metabolic measures, biomarkers and questionnaires as described below. 
METHODS AND ANALYSES
Study design, randomisation and blinding
This is an investigator-initiated, randomised, placebo-controlled, double-blinded, twoarm parallel group intervention trial carried out in non-diabetic women with previous GDM. Participants with previous GDM will be randomised to treatment with liraglutide or placebo after the baseline experiments. Adequate randomisation will be ensured by stratification based on a computer-generated random number sequence (1:1) with stratified block (permuted-block size) with participants stratified according to the baseline glucose tolerance: NGT versus non-NGT (impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or combined IFG/IGT). Participants with T2D at baseline will not be included in the trial. The randomisation will be carried out through a central independent unit via an unblinded data manager at Public Health and Quality Improvement, Central Denmark Region, Denmark. The allocation sequence will be concealed from the investigators and healthcare staff enrolling and assessing participants. Trial medication will be allocated via the electronic case report form (eCRF). The unblinded person will be impartial and have no influence or knowledge of the treatment of the participants following randomisation. Participants, investigators and healthcare staff will remain blinded for the allocated treatment and kept masked until the afternoon of visit 10 (OGTT after 1 year). Data analysis will be carried out blinded.
Study population and study sites
Ninety eight participants will participate in the randomised trial and 15 healthy women without previous GDM will make up a baseline control group. The trial will be conducted at the Diabetes Research Division, Copenhagen University Hospital Gentofte, Denmark. Recruitment will take place by an invitation letter send to all women, who have been diagnosed with GDM at either Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark or Department of Gynaecology-Obstetrics, Copenhagen University Hospital Herlev, Denmark, within the last 10 years. Moreover, participants will be recruited from advertisements in newspapers and on the internet. Total number of subjects in the following categories will be recorded: invited, excluded before screening (including reasons for exclusion), declined to participate, not reached, received participants information and declined, screened, excluded at screening, randomised, allocated for intervention, received allocated intervention, completed intervention period, withdrew/dropped out during study period (including reason for withdrawal/dropping out), lost to follow-up, and analysed. Recruitment is planned to proceed until 49 participants in each group have been randomised. Reasons for withdrawal or exclusion will be reported in details.
Inclusion and exclusion criteria are presented in Box 1 and Box 2. 
BOX 1 -Inclusion criteria
Inclusion criteria -women with previous gestational diabetes mellitus (GDM)
• Informed oral and written consent
• Age ≥18 years • Pregnancy within the last ten years without GDM
• No family history of type 2 diabetes
• Negative pregnancy test 
BOX 2 -Exclusion criteria
Exclusion criteria -women with previous gestational diabetes mellitus (GDM)
• Pregnancy or breast feeding
• Anaemia (haemoglobin <7 mmol/l)
• Diabetes (fasting plasma glucose (FPG) >7.0 mmol/l or plasma glucose (PG)
concentration at 120 min after 75g-oral glucose tolerance test ≥11.1 mmol/l or glycated haemoglobin A 1c (HbA 1c ) ≥48 mmol/mol (6.5%))
• Previous pancreatitis
• Cancer within the last five years
• Desire to become pregnant within the next five years
• Treatment with statins, corticosteroids, or other hormone therapy (except estrogens and gestagens)
• Ongoing abuse of alcohol or narcotics
• Impaired hepatic function (liver transaminases >3 times upper normal limit)
• Impaired renal function (se-creatinine >120 µM and/or albuminuria)
• Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg)
• Receiving any investigational drug within the last 3 months
• Any condition that the investigator feels would interfere with trial participation
Exclusion criteria -women without previous gestational diabetes mellitus
• Pregnancy or breastfeeding
• Anaemia (haemoglobin <7 mmol/l) 
Experimental design
Eligible participants will receive detailed oral and written information about the study.
Sufficient time for reflection will be allowed before written informed consent and authorisation are obtained. Both groups will attend the same visits unless stated
otherwise. An initial screening visit will be followed by a baseline OGTT and an isoglycaemic intravenous glucose infusion (IIGI) (Fig. 1) .
Following baseline OGTT, IIGI and other baseline procedures (including blood sampling, full body dual energy X-ray absorptiometry (DXA) scanning, glucagon test, imaging of the liver (ultrasound elastography and fibro-scanning) ( Fig. 1) ), the participants are randomised to once-daily injections of either liraglutide 1.8 mg or
placebo. In the 1-year intervention period, the participants will be monitored at regular clinical control visits and phone calls. At the end of the intervention period, the OGTT will be repeated, as well as all other procedures made at baseline, with an additional OGTT after 1-week washout in the liraglutide-treated group. Finally, an IIGI, matching the blood glucose profile of the latter OGTT, will be conducted in both groups. Both groups will attend biannual control visits in the 4-year follow-up period and terminate the study with the same experimental days as at the end of the intervention period. The women without previous GDM will only participate in the study for the baseline OGTT and IIGI experimental days and their related baseline
procedures. An outline of the trial visits and experimental procedures is shown in Box 3. On the initial screening day, fasting blood samples (Table 1) will be collected to verify that the participant fulfils the inclusion and exclusion criteria, medical history will be recorded and a full physical examination will be performed. All participants are required to use adequate contraceptive methods throughout the intervention and follow-up period. Intrauterine device will be offered. • Albumin
BOX 3 -Trial visits and examinations
• ALT, AST, amylase
• Cholesterol, triglycerides
• Creatinine, potassium, sodium
• Erythrocytes
• Glycated haemoglobin (HbA 1c )
• Haemoglobin
• Leucocytes
• TSH
Screening and control visits
• Glucose
• Insulin, proinsulin, C-peptide Screening, control visits,
OGTT, IIGI and glucagon test
• Glucose-dependent insulinotropic polypeptide (GIP)
• Glucagon
• Glucagon-like peptide-1 (GLP-1)
• Glucagon-like peptide-2 (GLP-2)
OGTT and IIGI
• Beta hCG
• Coagulation factor 2, 7 and 10
• Urine albumin:creatinine ratio Screening Within 10 days of the screening visit, a 4h 75g-OGTT will be performed. The participant will ingest 75 g glucose dissolved in 300 ml water over 5 minutes and, subsequently; repeated blood samples for measurements of PG, insulin, C-peptide, glucagon, GLP-1, and GIP will be drawn throughout the test. At baseline and once an hour afterwards, the participants will answer a questionnaire on appetite using a visual analogue scale (VAS) on a tablet-computer. If the 2h PG value is below 11.1 mmol/l, the participant will be randomised. At visit 10 (after 1 year) and 20 (after 5 years) a glucagon test will be carried out at the end of the OGTT. Within 10 days of the OGTT, the participants will attend an IIGI. In the morning of the IIGI, they are first DXA scanned, and their liver will be assessed by ultrasound scanning and fibroscanning (26). Over the next 4 hours, the PG curve from the OGTT day will be mimicked using a 20% glucose intravenous infusion. Again, repeated blood samples will be drawn and questionnaires answered as on the OGTT day, although PG may be sampled more frequently to adjust the glucose infusion rate. Two additional questionnaires, one regarding quality of life (QoL) and one regarding alcohol consumption habits, will be filled out once during the IIGI. At the end of the IIGI, a glucagon test will be performed; at time point 0 min 1 mg glucagon will be injected and at time points 2, 6, and 10 minutes, blood will be sampled for measurements of PG, insulin and C-peptide. Next, the participants are offered an ad libitum meal consisting of pasta, minced meat, vegetables and cream, which they are instructed to eat as much of "until comfortably satisfied" in addition to drinking 500 ml water. The distribution of energy in the ad libitum meal is 50 energy percent (E%) carbohydrates, 37 E% fat, and 13 E% protein. Additional palatability ratings (palatability, taste, aftertaste, smell, and visual appeal) of the meal are filled in immediately after the first few bites and after consumption of the ad libitum meal using VAS scores on a tablet.
The participants are then instructed in how to inject the trial medication, and how to measure blood glucose (Contour; Bayer HealthCare, Copenhagen, Denmark) twice a month and record it in a diary. One and eight weeks after the IIGI day, the participants will be contacted by phone for clarification of any questions they may have and any adverse events are recorded in the eCRF. Four, 12, 26 and 38 weeks after the IIGI, and biannually in the follow-up period, participants will meet in the fasting state for clinical control visits. Measurements of weight, waist-hip-ratio, blood pressure and pulse, compliance, and adverse events will be recorded, and trial medication will be dispensed. At 52 weeks, the OGTT will be repeated for both groups and placebo will be initiated for one week in both groups. An additional OGTT day will be carried out in the liraglutide-group to evaluate glucose tolerance off trial medication. Finally, an IIGI, as described above, will be conducted in both groups, matching the blood glucose profile of the latest OGTT. The exact same setup will be repeated at the end of the 4 year follow-up period. 
Intervention
Trial medication will be initiated at the end of the IIGI day in a dosage of 0.6 mg sc.
once daily. All participants will be instructed to inject the medicine in the abdomen once daily. Trial medication dose will be escalated over three weeks with onceweekly dose adjustments in increments of 0.6 mg to a maximal dose of 1.8 mg. If intolerable adverse events occur, the dose may be reduced to 1.2 mg, or the participant may remain on 1.2 mg for more than a week before increasing the dose.
Trial medication will be delivered in boxes of 5 pre-filled, disposable pen-injectors each containing 3 ml of a premixed colourless solution. The active pens will contain liraglutide (6 mg/ml) mixed with sterile water, disodium phosphate dihydrate, propylene glycol, and phenol. Pens containing placebo will be visually identical to those with the active component and be composed of sterile water, disodium phosphate dihydrate, propylene glycol, and phenol.
Outcome measures and analysis methods
Primary endpoint
The primary endpoint is the change in glucose tolerance from baseline to week 52 as measured by the AUC for the PG excursion following a 4h 75g-OGTT. Additional endpoints regarding glucose tolerance include changes from baseline to week 53 (after trial medication wash-out), to week 260 (end of extension period), and to week 261 (after trial medication washout). The primary endpoint will be analysed by the intention-to-treat approach. In case of missing data points, values will be imputed.
Safety measures will be analysed in the per protocol population. In case the full intervention period has not been completed, we will use the 'last observation carried forward' method.
Secondary endpoints
All secondary endpoints will be assessed as changes from baseline until 52 weeks, and until the end of the extension period (260 weeks). In addition, most endpoints will 
Sample size
The primary outcome measure was used in the sample size calculation. With respectively, and with alpha set to 5% and power to 90%, the estimated sample size was 98 participants (49 participants in each arm).
Data analysis
Continuous data will be presented by descriptive statistics with the number of observations (n), mean, standard deviation, standard error of the mean, minimum,
Changes in
• Anthropometric measurements (BMI, absolute body weight, and waist: hip ratio)
• Beta cell secretory responses during OGTT, IIGI, and glucagon test (AUC for plasma insulin, C-peptide and pro-insulin)
• Insulin sensitivity (assessment of insulin resistance (HOMA IR ) and Matsuda insulin sensitivity index)
• Hormone secretion (fasting plasma concentrations and AUC for plasma GLP-1, GLP-2, GIP, and glucagon) during OGTT
• Incretin effect and insulin secretory rate (AUC for plasma insulin and C-peptide responses after OGTT and IIGI)
• Cardio-metabolic risk measures (changes in ELF test, intrahepatic fat, whole body and visceral fat mass/fat-free mass, circulating lipids, and cardiovascular biomarkers (hs-CRP, NT-proBNP, TNF-α, adiponectin, and PAI-1)
• Subjective appetite (measured by VAS)
• QoL (measured by validated questionnaire)
• Alcohol consumption (measured by validated questionnaire) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y 18 median, and/or maximum. Categorical data will be summarised in frequency tables using count and percentages. All participants will be presented in separate data listings. Data from participants screened, but not randomised, will not be presented in any tables or listings. Comparisons of data from the two treatment groups will be performed using two-tailed t test (paired within groups, unpaired between groups) if the data are normally distributed. For data which are not normally distributed, the significance of differences between the groups will be tested using Mann-Whitney Utest. For within-group comparisons, Wilcoxon test for paired differences will be used.
One-way ANOVA will be used to compare means of several groups. Categorical data will be analysed by chi-square test or Fisher´s exact test. The relationship between an effect of liraglutide and hip, waist, and weight measures, visceral fat mass, FPG, HbA 1c , degree of steatosis, QoL, alcohol consumption, appetite, respectively, will be examined by correlation analysis. Multivariable linear regression analysis will be performed to evaluate the potential influence of predictors of primary outcomes. All tests will be carried out at a significance level of 5%. Adverse events (AEs) will be summarised qualitatively and quantitatively.
ETHICS AND DISSEMINATION Ethics
The treatment is associated with minimal discomfort for the participants comprising blood sample collection and daily injection of liraglutide or placebo in the subcutis of the abdomen, in the thigh, or the upper arm. Common adverse events associated with the active comparator (liraglutide) are mild to moderate transient gastrointestinal symptoms (nausea, vomiting and diarrhoea), affecting around 10-15% of treated patients, and headache. The injection is practically pain-free but may leave a small haemorrhage which will resolve spontaneously. Less commonly, participants may experience stomach pain, constipation, fever, reflux, gastritis, dizziness, tiredness, and upper airway infection. When collecting blood, some participants may experience minor discomfort when the needle penetrates the skin and rarely a small bleeding occurs. The volume of blood collected during the entire study period will amount to a A DXA scan will be performed 3 times during the study with the objective of determining the distribution of bone and adipose tissue. DXA scanning takes 15 minutes is a painless procedure with no expected side effects, and results in a modest radiation dose (approximately equivalent to 2-3 times the dose received from a dental X-ray). Scanning of the liver will be carried out using ultrasound. Ultrasound creates images using sound waves and no side effects are expected from this procedure.
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